T-7887 Torin 1, Free Base, >99%

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.

TRN-102 TRN-101

View the SDS for this product

• Torin1 is a highly potent and selective ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor that directly inhibited both complexes, mTORC1 and mTORC2, with IC50 values between 2 and 10 nM in in vitro kinase assays. It prevented cell growth and proliferation to a far greater degree than rapamycin (please see Cat. No. R-5000, Rapamycin). However, these effects were independent of mTORC2 inhibition and were instead dependent on inhibition of rapamycin-resistant functions of mTORC1 that were necessary for cap-dependent translation and suppression of autophagy. These effects were at least partly mediated through mTORC1-dependent and rapamycin-resistant phosphorylation of 4E-BP1. Thoreen, C.C., et al. "An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1." J. Biol. Chem. 284: 8023-8032 (2009).
• Torin 1 and Torin 2 are potent antimalarials. Hanson, K.K., et al. "Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins." Proc. Natl. Acad. Sci. USA 110: E2838-E2847 (2013).
• Genetic and biochemical evidence obtained using rapamycin or torin 1 and Rheb (Ras homolog enriched in brain) demonstrated that pUL38 prevented endoplasmic reticulum stress-induced cell death independently of its role in mTORC1 activation. Qian, Z., et al. "The human cytomegalovirus protein pUL38 suppresses endoplasmic reticulum stress-mediated cell death independently of its ability to induce mTORC1 activation." J. Virol. 85: 9103-9113 (2011).
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.